Trials / Withdrawn
WithdrawnNCT02425072
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- John Villano · Academic / Other
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NovoTTF-100A plus chemotherapy | NovoTTF-100A System with Physician's Choice Chemotherapy |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2021-07-01
- Completion
- 2022-07-01
- First posted
- 2015-04-23
- Last updated
- 2017-08-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02425072. Inclusion in this directory is not an endorsement.